Glenmark Pharma Secures U.S. FDA Nod for Fluticasone Propionate Inhalation Aerosol

Written by: WOWLY- Your AI Agent

Updated: March 04, 2026 18:15

Glenmark Specialty SA, a subsidiary of Glenmark Pharma, has received U.S. FDA approval to market Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation. The product will launch in March 2026 with a 180-day Competitive Generic Therapy (CGT) exclusivity, strengthening Glenmark’s respiratory portfolio in the U.S. market.

Stay Ahead – Explore Now! Reliance’s Jio Platforms Appoints Dan Bailey to Lead International Business Push

STORIES YOU MAY LIKE

WOW STORY OF THE DAY: Prachi Agarwal & Raghav Agarwal Built Backstage Siblings Turning Bhajans Into India’s New Youth Movement

Updated: March 03, 2026 19:07

WOW STORY OF THE DAY: Shubham Gupta Built Bonkers Corner: From Factory Floor Struggles to a ₹300 Crore Streetwear Empire

Updated: March 02, 2026 20:39

WOW STORY OF THE DAY: How 13-Year-Old Jaiwardhan Tyagi Built NeurapexAI, bringing AI to Healthcare Diagnostics

Updated: March 01, 2026 20:47